CervoMed (CRVO)

• Market cap: $47.8M
• 1 day: -6.16%
• 5 days: 170.56%
• 1 month: 164.38%
• 3 months: 204.74%
• 6 months: -66.93%
• Year to date: 159.64%
• 1 year: -65.92%
• 5 years: -62.65%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 8

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

6% less funds holding

Funds holding: 49 [Q3] → 46 (-3) [Q4]

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

24.53% less ownership

Funds ownership: 42.54% [Q3] → 18.01% (-24.53%) [Q4]

93% less capital invested

Capital invested by funds: $51.2M [Q3] → $3.46M (-$47.8M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 73% upside
• Avg. target: $13.50 133% upside
• High target: $15 159% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Soumit Roy 19% 1-year accuracy 3 / 16 met price target	159% upside $15	Buy Upgraded	13 Mar 2025
Chardan Capital Daniil Gataulin 22% 1-year accuracy 9 / 41 met price target	142% upside $14	Buy Upgraded	13 Mar 2025
Roth MKM Boobalan Pachaiyappan 44% 1-year accuracy 4 / 9 met price target	159% upside $15	Buy Maintained	11 Mar 2025
D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target	73% upside $10	Buy Maintained	11 Mar 2025